(ShareCast News) - Medical research company Vectura Group said it has triggered another $3m (£1.98m) milestone payment for its VR315 treatment.Vectura, which specialises in the development of products for the treatment of airways-related diseases, said it had already earned $9m (£6m) from the deal it has with the unnamed US division of a "leading international pharmaceutical company".VR315 is a generic, inhaled combination therapy for asthma and chronic obstructive pulmonary disease using Vectura's proprietary dry powder inhaler and formulation technology.The company signed a licence agreement with the for the development, manufacturing and commercialisation of VR315 in the US in 2011.Vectura is eligible to receive a further $23m upon achievement of future pre-determined development milestones. These milestones, together with the initial payment of $10m in August 2011, total $45m. In addition, Vectura will receive a royalty from all sales of VR315 in the US.